Background: Functional dyspepsia (FD) is a gastrointestinal disorder affecting people in the globe. Spleen-deficiency syndrome is one of its basic syndromes. Zhizhu Kuanzhong capsule was the most frequent Chinese herbal formula used in the spleen-deficiency researches. We aim to assess the effectiveness and safety of Zhizhu Kuanzhong capsule on FD.
Methods: A systematic literature search for randomized controlled trials (RCTs) from their inception until December 31, 2017 will be conducted using 7 databases: PubMed, Cochrane Library, Embase, VIP Database, Chinese National Knowledge Infrastructure, Wanfang Data, and Chinese BioMedical Database. Inclusion the trials of Zhizhu Kuanzhong capsule which evaluate motilin level, clinical syndrome, and side effect in people with FD. The primary outcome measures will be motilin level, clinical syndrome integral, and clinical total effective rate. Data extraction and risk of bias assessments will be performed by 2 reviewers independently. Methodological and reporting quality of included studies will be assessed by the consolidated standards of reporting trials for Chinese herbal medicine formulas. All statistical analyses will be conducted using RevMan V.5.3 software. Funnel plots, Begg's test, and Egger's test will be developed to evaluate reporting bias.
Results: This review will assess the effect of Zhizhu Kuanzhong capsule on clinical total effective rate, symptom remission rate, plasma motilin level, and safety of FD in patients.
Conclusion: The conclusion of our study will provide updated evidence to judge whether Zhizhu Kuanzhong capsule is an effective intervention for patients with FD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944680 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000009731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Network Meta-analysis of oral Chinese patent medicine combined with conventional western medicine in treatment of gastro-esophageal reflux disease].
Zhongguo Zhong Yao Za Zhi
September 2024
Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
Article Synopsis
- The study evaluated the effectiveness and safety of oral Chinese patent medicines combined with conventional western medicine for treating gastro-esophageal reflux disease (GERD) through a network meta-analysis of randomized controlled trials.
- A total of 47 studies involving 10 different Chinese patent medicines were analyzed, with Dalitong Granules, Liuwei Anxiao Capsules, Weisu Granules, and Xiaoyao Pills showing the best effectiveness based on various criteria (clinical symptoms, endoscopic results, serum gastrin, and plasma motilin levels).
- The results indicated that combining these Chinese medicines with conventional treatment leads to better outcomes in symptom improvement and quality of life compared to conventional treatment alone, without significant differences in adverse reactions.
Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia: A Randomized Controlled Trial.
J Neurogastroenterol Motil
July 2023
Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- The study compares the effectiveness of Zhizhu Kuanzhong capsules (ZZKZ) and doxepin hydrochloride in treating functional dyspepsia (FD) and addressing the stigma around antidepressants.
- Patients taking ZZKZ showed higher medication adherence and a reduction in stigma compared to those taking doxepin, with significant differences in outcomes between the two medications.
- Both treatments improved dyspeptic symptoms and psychological conditions similarly, but ZZKZ was more effective in reducing stigma and improving medication compliance.
Zhizhu Kuanzhong, a traditional Chinese medicine, alleviates gastric hypersensitivity and motor dysfunction on a rat model of functional dyspepsia.
Front Pharmacol
November 2022
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhizhu Kuanzhong (ZZKZ) is a traditional Chinese medicine modified from classic formula Zhizhu decoction in "Synopsis of Golden Chamber" (Han Dynasty in the 3 century) and the Zhizhu pill in "Differentiation on Endogenous" in Jin Dynasty (1,115-1,234). ZZKZ contains four botanical drugs, including L [Rutaceae; ], Koidz. [Compositae; ], DC [Apiaceae; ], and Bunge [Rosaceae; ], which have been widely used in clinical therapy for functional dyspepsia (FD).
View Article and Find Full Text PDF[Four Chinese patent medicines for regulating stomach for functional dyspepsia: a rapid health technology assessment].
Zhongguo Zhong Yao Za Zhi
September 2022
Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700, China.
This study evaluated and compared the efficacy, safety and economy of four Chinese patent medicines(CPMs) in the treatment of functional dyspepsia(FD) using the method of rapid health technology assessment. It aims to provide decision-makers with rapid decision-making information. The eight Chinese and English databases were comprehensively and systematically searched for the relevant clinical research.
View Article and Find Full Text PDFZhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial.
Trials
June 2022
NMPA Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine and National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders. Based on the various symptoms present in patients with functional dyspepsia postprandial distress syndrome (FD-PDS), routine agents such as acid suppressants, prokinetic drugs, and centrally acting drugs, offer limited treatment choices with potential side effects. As a preliminary clinical trial showed that the marketed product Zhizhu Kuanzhong Capsule (ZZKZ) can improve symptoms in FD-PDS patients, our study aims to provide further evidence on the clinical efficacy and safety of ZZKZ in the treatment of patients with FD-PDS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!